LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.

MLA

Lee, Alexandria T. M., and Sai-Hong Ignatius Ou. “LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.” Lung Cancer (Auckland, N.Z.), vol. 15, May 2024, pp. 75–80. EBSCOhost, https://doi.org/10.2147/LCTT.S460147.

APA

Lee, A. T. M., & Ou, S.-H. I. (2024). LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.), 15, 75–80. https://doi.org/10.2147/LCTT.S460147

Chicago

Lee, Alexandria T M, and Sai-Hong Ignatius Ou. 2024. “LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.” Lung Cancer (Auckland, N.Z.) 15 (May): 75–80. doi:10.2147/LCTT.S460147.